11714655

Source:http://linkedlifedata.com/resource/pubmed/id/11714655

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0022116, umls-concept:C0035126, umls-concept:C0243192, umls-concept:C0289313, umls-concept:C1335238, umls-concept:C1515655, umls-concept:C1522564, umls-concept:C1545588
pubmed:issue	21
pubmed:dateCreated	2001-11-20
pubmed:abstractText	Diabetes is associated with increased risk of mortality as a consequence of acute myocardial infarction. This study determined whether rosiglitazone (ROSI) could reduce myocardial infarction after ischemia/reperfusion injury.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0147763
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD18, http://linkedlifedata.com/resource/pubmed/chemical/Cell Adhesion Molecules, http://linkedlifedata.com/resource/pubmed/chemical/Chemokine CCL2, http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Macrophage-1 Antigen, http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Cytoplasmic and Nuclear, http://linkedlifedata.com/resource/pubmed/chemical/Thiazoles, http://linkedlifedata.com/resource/pubmed/chemical/Thiazolidinediones, http://linkedlifedata.com/resource/pubmed/chemical/Transcription Factors, http://linkedlifedata.com/resource/pubmed/chemical/rosiglitazone
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	1524-4539
pubmed:author	pubmed-author:BanHH, pubmed-author:BoyceRR, pubmed-author:BrixMM, pubmed-author:BuckinghamR ERE, pubmed-author:ChenJJ, pubmed-author:FOYHH, pubmed-author:HartT KTK, pubmed-author:JiangWW, pubmed-author:LyskoP GPG, pubmed-author:NarayananP KPK, pubmed-author:OhlsteinE HEH, pubmed-author:Yue TlT LTL, pubmed-author:ZimmermanD MDM
pubmed:issnType	Electronic
pubmed:day	20
pubmed:volume	104
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	2588-94
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:11714655-Animals, pubmed-meshheading:11714655-Antigens, CD18, pubmed-meshheading:11714655-Cell Adhesion Molecules, pubmed-meshheading:11714655-Chemokine CCL2, pubmed-meshheading:11714655-Diabetes Complications, pubmed-meshheading:11714655-Hypoglycemic Agents, pubmed-meshheading:11714655-Macrophage-1 Antigen, pubmed-meshheading:11714655-Macrophages, pubmed-meshheading:11714655-Male, pubmed-meshheading:11714655-Monocytes, pubmed-meshheading:11714655-Myocardial Contraction, pubmed-meshheading:11714655-Myocardial Infarction, pubmed-meshheading:11714655-Myocardial Reperfusion Injury, pubmed-meshheading:11714655-Neutrophil Infiltration, pubmed-meshheading:11714655-Neutrophils, pubmed-meshheading:11714655-RNA, Messenger, pubmed-meshheading:11714655-Rats, pubmed-meshheading:11714655-Rats, Inbred Lew, pubmed-meshheading:11714655-Receptors, Cytoplasmic and Nuclear, pubmed-meshheading:11714655-Thiazoles, pubmed-meshheading:11714655-Thiazolidinediones, pubmed-meshheading:11714655-Transcription Factors
pubmed:year	2001
pubmed:articleTitle	In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
pubmed:affiliation	Department of Cardiovascular Pharmacology, GlaxoSmithKline Pharmaceuticals, King of Prussia, PA, USA.
pubmed:publicationType	Journal Article